BEVERLY, Mass., Aug. 15 /PRNewswire/ -- CutisPharma, Inc. announced today that its FIRST(TM) Unit-of-Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter <795>: Pharmaceutical Compounding-Nonsterile Preparations Guidelines. The purpose of the chapter is to establish standards, and to enhance the compounder’s ability to extemporaneously compound preparations that are of acceptable strength, quality, and purity. “It is our understanding that the use of FIRST(TM) Kits by pharmacists for their compounding needs facilitates their compliance with USP Chapter <795>. Also, the use of FIRST(TM) Kits will assist various regulatory authorities in monitoring compliance with USP Chapter <795>, particularly in the Compounding Records and Documentation section,” stated Dr. Indu Muni, Chairman and CEO of CutisPharma. “Quality assurance and control are key to better customized patient care. Any improvement in standardization for pharmacy compounding is what all leaders in the compounding world are working toward,” added Dr. Muni.
CutisPharma offers an easy and time-saving solution to compounded prescriptions. FIRST(TM) Unit of Use Compounding Kits provide standardized drug delivery. Pre-measured, pre-weighed components enable pharmacists to dispense prescribed dosage first time, every time. FIRST(TM) products save dispensing time, and increase efficiencies in pharmacy operations. A single NDC number assigned for the entire Kit for each product offers easy third party reimbursement and reduces audit related adjustments.
FIRST(TM) Kits can be compounded by the Pharmacist while the Patient waits, increasing customer satisfaction. CutisPharma currently has seven proprietary prescription compounding kits on the market: three progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and one Magic Mouthwash kit. Several more compounding kits are in the planning stages.
The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through “compounding,” a means by which a pharmacist prepares a customized medication according to a doctor’s prescription to meet an individual patient’s medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.
About CutisPharma
CutisPharma, Inc. based in Beverly, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(TM) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely Physicians, Pharmacists, and Patients. A U.S. patent has been issued to the Company and additional patents are pending.
Contact: James Nagle V.P. Business Development CutisPharma, Inc. 978-867-1010 x20 jnagle@cutispharma.com
For more information please visit our website at http://www.cutispharma.com.
CutisPharma, Inc.
CONTACT: James Nagle, V.P. Business Development, of CutisPharma, Inc.,+1-978-867-1010, Ext. 20, jnagle@cutispharma.com
Web site: http://www.cutispharma.com/
